Treatment Options for Relapsed or Refractory Peripheral T-Cell Lymphoma

Source updated: May 13, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Treatment options for relapsed or refractory peripheral T-cell lymphoma include:

Combination chemotherapy.

ICE (ifosfamide, carboplatin, and etoposide).[1,2]

Source links and citations

Combination chemotherapy.

GEMOX (gemcitabine, oxaliplatin, and dexamethasone).[3]

Source links and citations

Combination chemotherapy.

DHAP (dexamethasone, high-dose cytarabine, and cisplatin).[4]

Source links and citations

Combination chemotherapy.

ESHAP (etoposide, methylprednisolone, high-dose cytarabine, and cisplatin).[5,6]

Source links and citations

Combination chemotherapy.

Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone).[7]

Source links and citations

Antibody conjugates.

Brentuximab vedotin (for CD30-positive patients).

Histone deacetylase inhibitors.

Romidepsin.[8]

Source links and citations

Histone deacetylase inhibitors.

Belinostat.[9,10]

Source links and citations

Dihydrofolate reductase inhibitors.

Pralatrexate.[11]

Source links and citations

Anti-CD52 monoclonal antibodies.

Alemtuzumab (only available through a restricted distribution program).

Stem cell transplant.[12-16]

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice